Syschem (India) Ltd
Incorporated in 1993, Syschem (India) Limited manufactures Active Pharmaceuticals Ingredients (APIs) and bulk drugs.
- Market Cap ₹ 221 Cr.
- Current Price ₹ 55.5
- High / Low ₹ 73.9 / 33.4
- Stock P/E 80.2
- Book Value ₹ 14.3
- Dividend Yield 0.00 %
- ROCE 10.7 %
- ROE 6.96 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company is expected to give good quarter
Cons
- Stock is trading at 3.89 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 9.29% over last 3 years.
- Debtor days have increased from 93.7 to 126 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
16 | 18 | 11 | 4 | 13 | 67 | 93 | 77 | 68 | 59 | 114 | 199 | |
12 | 14 | 14 | 5 | 12 | 63 | 89 | 77 | 73 | 58 | 105 | 192 | |
Operating Profit | 4 | 4 | -3 | -1 | 0 | 3 | 4 | -0 | -5 | 1 | 9 | 7 |
OPM % | 24% | 22% | -23% | -24% | 0% | 5% | 4% | -0% | -7% | 1% | 8% | 4% |
0 | 1 | 0 | 0 | -0 | -0 | -0 | 0 | -0 | 0 | 0 | 0 | |
Interest | 1 | 3 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Depreciation | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 3 | 3 |
Profit before tax | 1 | 1 | -5 | -3 | -2 | 1 | 2 | -2 | -7 | -2 | 6 | 4 |
Tax % | 29% | 21% | 26% | 27% | 30% | 43% | 50% | 16% | 24% | 22% | 27% | 33% |
1 | 1 | -4 | -2 | -1 | 0 | 1 | -2 | -6 | -2 | 5 | 3 | |
EPS in Rs | 0.49 | 0.30 | -1.94 | -1.13 | -0.75 | 0.17 | 0.32 | -0.79 | -2.07 | -0.59 | 1.13 | 0.69 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | 27% |
5 Years: | 16% |
3 Years: | 43% |
TTM: | 75% |
Compounded Profit Growth | |
---|---|
10 Years: | 17% |
5 Years: | 23% |
3 Years: | 36% |
TTM: | -39% |
Stock Price CAGR | |
---|---|
10 Years: | 22% |
5 Years: | 48% |
3 Years: | 102% |
1 Year: | 37% |
Return on Equity | |
---|---|
10 Years: | -6% |
5 Years: | -2% |
3 Years: | 9% |
Last Year: | 7% |
Balance Sheet
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 16 | 16 | 16 | 16 | 16 | 16 | 19 | 19 | 22 | 23 | 32 | 40 |
Reserves | -3 | -2 | -6 | -8 | -10 | -9 | -8 | -10 | -16 | -17 | -10 | 17 |
Preference Capital | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | |
30 | 31 | 27 | 26 | 21 | 19 | 15 | 16 | 15 | 2 | 2 | 0 | |
4 | 10 | 14 | 13 | 17 | 31 | 37 | 37 | 56 | 52 | 69 | 107 | |
Total Liabilities | 48 | 55 | 51 | 47 | 44 | 58 | 62 | 62 | 77 | 60 | 93 | 164 |
29 | 36 | 34 | 32 | 30 | 29 | 27 | 28 | 30 | 32 | 31 | 32 | |
CWIP | 4 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 4 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
14 | 18 | 16 | 15 | 14 | 28 | 35 | 34 | 46 | 28 | 62 | 128 | |
Total Assets | 48 | 55 | 51 | 47 | 44 | 58 | 62 | 62 | 77 | 60 | 93 | 164 |
Cash Flows
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
4 | 4 | 1 | 0 | 6 | 0 | -2 | 3 | 4 | 1 | -8 | -26 | |
-13 | -3 | 0 | 0 | 0 | 0 | 2 | -4 | -4 | -1 | 9 | -6 | |
10 | -1 | -2 | -1 | -7 | -0 | -0 | -0 | -0 | -0 | -0 | 32 | |
Net Cash Flow | 1 | 0 | -1 | 0 | -0 | 0 | 0 | -0 | -0 | 0 | 1 | -0 |
Ratios
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 115 | 143 | 187 | 272 | 124 | 47 | 21 | 47 | 31 | 21 | 135 | 126 |
Inventory Days | 214 | 280 | 228 | 868 | 182 | 80 | 104 | 110 | 199 | 152 | 61 | 107 |
Days Payable | 56 | 183 | 290 | 870 | 424 | 151 | 131 | 175 | 221 | 186 | 158 | 198 |
Cash Conversion Cycle | 273 | 240 | 124 | 271 | -119 | -24 | -7 | -19 | 9 | -14 | 38 | 34 |
Working Capital Days | 108 | 120 | 72 | 92 | -173 | -23 | -12 | -24 | 13 | -15 | 48 | 54 |
ROCE % | 8% | 8% | -11% | -8% | -6% | 3% | 8% | -8% | -29% | -13% | 39% |
Documents
Announcements
- As Per Regulation 47(3) Read With Schedule III Of SEBI (LODR) Regulations, 2015 Advertisement For The Quarter And Year Ending 31St March, 2024 7 May
- Pursuant To Regulation 33 Of SEBI (Listing Obligations And Disclosure Requirement), 2015, The Audited Results With Audited Report, Unmodified Opinion Report And Outstanding Borrowing Details For The Financial Year Ending 31St March, 2024 6 May
- Board Meeting Outcome for Outcome Of Board Meeting Dated 6Th May, 2024 For The Quarter And Year Ended 31St March, 2024 6 May
- Board Meeting Intimation for Pursuant To Regulation 29 Of SEBI (LODR), 2015, The Intimation For The Board Meeting Dated 6Th Of May, 2024 27 Apr
-
Compliance: Regulation 40(10) For The Year Ended 31 St March, 2024
25 Apr - Compliance as per regulation 40(10) of LODR, 2015 for the year ended 31st March, 2024.
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
-
Financial Year 2004
from bse
Product Profile:[1]
API/ Intermediates:
a) Amoxycillin Tri Hydrate
b) Ampicillin Tri Hydrate
c) Cloxacillin Sodium
d) Dicloxacillin Sodium
e) Flucloxacillin Sodium (For export only)
f) Cephalexin
g) Cefixime
h) Cefadroxil
i) Distillation of Specialty Solvents –
DMF, Acetonitrile, Ethyl Acetate and THF